[{"id":"2451850f-5b0c-4c08-aeda-4faec51709a8","acronym":"","url":"https://clinicaltrials.gov/study/NCT07045311","created_at":"2025-07-05T13:59:45.588Z","updated_at":"2025-07-05T13:59:45.588Z","phase":"Phase 2","brief_title":"JS207 Combination Therapy in Triple-negative Breast Cancer","source_id_and_acronym":"NCT07045311","lead_sponsor":"Shanghai Junshi Bioscience Co., Ltd.","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e albumin-bound paclitaxel • bulumtatug fuvedotin (9MW2821)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 07/01/2025","start_date":" 07/01/2025","primary_txt":" Primary completion: 03/22/2028","primary_completion_date":" 03/22/2028","study_txt":" Completion: 03/22/2029","study_completion_date":" 03/22/2029","last_update_posted":"2025-07-01"},{"id":"a74b2a6b-c53a-429a-a6e6-aeb6fe0acc78","acronym":"","url":"https://clinicaltrials.gov/study/NCT05216965","created_at":"2022-02-05T18:28:06.695Z","updated_at":"2024-07-02T16:36:08.717Z","phase":"Phase 1/2","brief_title":"A Clinical Study of 9MW2821 in Subjects With Advanced Malignant Solid Tumors","source_id_and_acronym":"NCT05216965","lead_sponsor":"Mabwell (Shanghai) Bioscience Co., Ltd.","biomarkers":" NECTIN4","pipe":" | ","alterations":" NECTIN4 expression","tags":["NECTIN4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NECTIN4 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bulumtatug fuvedotin (9MW2821)"],"overall_status":"Recruiting","enrollment":" Enrollment 208","initiation":"Initiation: 06/11/2022","start_date":" 06/11/2022","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2022-06-15"}]